Syngulon

Rue Du Bois Saint Jean 15/1
4102 Seraing
BE
Syngulon
Foundation date
07/03/2013
Sector
#Biotechnology - otherSubsector
Syngulon is developing original genetic technologies to improve the efficiency of microorganisms.Syngulon has introduced a new genetic technology (US Patent 9,333,227, issued on May 10, 2016) for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.This issued patent is part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive basis.
Upcoming events
All events-
2809 '22
NLSDays 2022
Event by: SwedenBIO -
2405 '22
PrecisionMed Expo & Summit
Event by: Smart Planet Media International -
2405 '22
EMERGE GHI
Event by: Smart Planet Media International
Latest news
More news-
Latest field trials validate strength of Biotalys’ first biocontrol Evoca
Thursday May 19th 2022
Read more
-
Belgian biotech in European Top-3 despite turbulent times
Wednesday May 18th 2022
Read more
-
KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus
Wednesday May 18th 2022
Read more